Evommune Presents Phase 2a Data for EVO301 in Atopic Dermatitis

Evommune, Inc. shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis at the European Academy of Dermatology and Venereology Congress.